Free Trial
NASDAQ:BLFS

BioLife Solutions Q3 2025 Earnings Report

BioLife Solutions logo
$28.52 -0.23 (-0.78%)
As of 11:29 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

BioLife Solutions EPS Results

Actual EPS
N/A
Consensus EPS
-$0.01
Beat/Miss
N/A
One Year Ago EPS
N/A

BioLife Solutions Revenue Results

Actual Revenue
N/A
Expected Revenue
$25.69 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

BioLife Solutions Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Tuesday, November 11, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

BioLife Solutions Earnings Headlines

BioLife Solutions (BLFS) Gets a Buy from Northland Securities
BioLife Solutions (BLFS) Receives a Buy from Jefferies
Another gold high? Here’s the move Wall Street is missing …
Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says the real opportunity is in a little-known strategy that has historically outpaced gold’s rallies many times over — including one past run where investors saw gains of more than 26,000%.tc pixel
See More BioLife Solutions Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BioLife Solutions? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioLife Solutions and other key companies, straight to your email.

About BioLife Solutions

BioLife Solutions (NASDAQ:BLFS) (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies. In addition to its core media and instrumentation, BioLife provides technical support, training and validation services to help customers integrate its products into regulated processes and meet GMP-compliance requirements.

Headquartered in Bothell, Washington, BioLife Solutions serves a global customer base spanning academic research centers, contract development and manufacturing organizations (CDMOs) and commercial biopharmaceutical companies. The company has established distribution channels in North America, Europe and Asia to support the growing demand for standardized, clinical-grade preservation solutions. BioLife’s management team is led by President and Chief Executive Officer Warren T. Thompson, whose experience in the life sciences industry has guided strategic product development and expansion initiatives. Through continuous innovation in biopreservation technologies, BioLife Solutions aims to enable the safe and reliable delivery of next-generation cell therapies worldwide.

View BioLife Solutions Profile

More Earnings Resources from MarketBeat